Tracking the immunoregulatory mechanisms active during allograft tolerance

Journal of Immunology

Volumn 168, Issue 5, 2002, Pages 2274-2281

  Sánchez Fueyo, Alberto ^a   Weber, Martina ^a   Domenig, Christoph ^a   Strom, Terry B ^a   Xin, Xiao Zheng ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 2;

ADOPTIVE TRANSFER; ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0036498560     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.168.5.2274     Document Type: Article

References (33)

1. Transplantation tolerance: Fooling mother nature
2. T cell death and transplantation tolerance
3. Blocking both signal 1 and signal 2 of T cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance
4. Requirement for T cell apoptosis in the induction of peripheral transplantation tolerance
5. Impaired alloantigen-mediated T cell apoptosis and failure to induce long-term allograft survival in IL-2-deficient mice
6. Quantifying the frequency of alloreactive T cells in vivo: New answers to an old question
7. Infectious tolerance
8. + regulatory cells?
9. "Infectious" transplantation tolerance
10. Prolongation of organ allograft survival by syngeneic lymphoid cells
11. Transfer of specific unresponsiveness to organ allografts by thymocytes: Specific unresponsiveness by thymocyte transfer
12. Suppressor T cells in rats with prolonged cardiac allograft survival after treatment with cyclosporine
13. Mechanisms maintaining enhancement of allografts. I. Demonstration of a specific suppressor cell
14. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine: Mediation of specific suppression by T helper/inducer cells
15. Development of suppressor lymphocytes during acute rejection of rat cardiac allografts and preservation of suppression by anti-IL-2-receptor monoclonal antibody
16. + T cells mediate the induction of immunologic unresponsiveness in enhanced rat recipients of cardiac allografts
17. Two phenotypically distinct populations of T cells have suppressor capabilities simultaneously in the maintenance phase of immunologic enhancement
18. + suppressor cell and its mechanisms of action
19. Thymus and autoimmunity: Capacity of the normal thymus to produce pathogenic self-reactive T cells and conditions required for their induction of autoimmune disease
20. + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
21. + T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells
22. + immunoregulatory T cells that control autoimmune diabetes
23. + immunoregulatory T cells is antigen nonspecific
24. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo
25. + immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade
26. IL-2 knockout recipient mice reject islet cell allografts
27. IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice
28. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39
29. Distinct mechanisms for the induction and maintenance of allograft tolerance with CTLA4-Fc treatment
30. + CD45RB low-density cells from untreated mice prevent acute allograft rejection
31. + regulatory cells that control intestinal inflammation
32. + suppressor T cells
33. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment